Dapagliflozin Started During Heart Failure Hospitalisation: DAPA ACT HF-TIMI 68
ABSTRACT:
Study at a glance
- Publication type: Randomised, double-blind, placebo-controlled trial with meta-analysis
- What it examined: DAPA ACT HF-TIMI 68 tested in-hospital initiation of dapagliflozin 10 mg daily in 2,401 patients hospitalised for heart failure.
- Key point: At two months, the trial primary composite of cardiovascular death or worsening heart failure was not significantly reduced (hazard ratio 0.86; 95% CI 0.68-1.08). In the prespecified meta-analysis of randomised in-hospital SGLT2 inhibitor trials, the composite was reduced (HR 0.71; 95% CI 0.54-0.93).
Why it matters
The study distinguishes an individual trial result from the wider randomised evidence base. Treatment decisions remain individual clinical decisions, including assessment of blood pressure, kidney function and contraindications.
Source
Berg DD, et al. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis. Circulation. 2025. PMID: 40884036. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
